Your browser doesn't support javascript.
loading
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A; Raynaud, Florence I; Levy, Gallia; Ware, Joseph A; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M; Lackner, Mark R; Yan, Yibing; Friedman, Lori S; Kaye, Stan B; Derynck, Mika K; Workman, Paul; de Bono, Johann S.
Afiliação
  • Sarker D; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Ang JE; The Institute of Cancer Research, London, United Kingdom.
  • Baird R; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Kristeleit R; The Institute of Cancer Research, London, United Kingdom.
  • Shah K; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Moreno V; The Institute of Cancer Research, London, United Kingdom.
  • Clarke PA; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Raynaud FI; The Institute of Cancer Research, London, United Kingdom.
  • Levy G; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Ware JA; The Institute of Cancer Research, London, United Kingdom.
  • Mazina K; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Lin R; The Institute of Cancer Research, London, United Kingdom.
  • Wu J; The Institute of Cancer Research, London, United Kingdom.
  • Fredrickson J; The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, United Kingdom.
  • Spoerke JM; Genentech Inc., South San Francisco, California, United States of America.
  • Lackner MR; Genentech Inc., South San Francisco, California, United States of America.
  • Yan Y; Genentech Inc., South San Francisco, California, United States of America.
  • Friedman LS; Genentech Inc., South San Francisco, California, United States of America.
  • Kaye SB; Genentech Inc., South San Francisco, California, United States of America.
  • Derynck MK; Genentech Inc., South San Francisco, California, United States of America.
  • Workman P; Genentech Inc., South San Francisco, California, United States of America.
  • de Bono JS; Genentech Inc., South San Francisco, California, United States of America.
Clin Cancer Res ; 21(1): 77-86, 2015 Jan 01.
Article em En | MEDLINE | ID: mdl-25370471
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase / Indazóis / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase / Indazóis / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido